Immune drug shows promise against tough brain cancers
NCT ID NCT03718767
First seen Dec 08, 2025 · Last updated Jun 09, 2026 · Updated 25 times
Summary
This study tests if the immunotherapy drug nivolumab can stop or slow the growth of certain brain tumors (gliomas) that have IDH mutations. Researchers are especially interested in tumors with many genetic changes (hypermutator phenotype). The trial involves 62 adults who receive the drug intravenously every few weeks. The main goal is to see how long the tumor stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.